The SCI offers Innovation Awards to support projects focused on the acceleration of basic, translational, clinical and population-based cancer research, and projects focused on specific types of cancer, such as pancreatic, breast and gynecologic cancers. This award cycle, we encourage proposals related to the Priority Cancers-Breast, Pancreatic, Liver, Lung, and Lymphoma. Full announcement >>

AWARD CATEGORIES:

• Stanford Cancer Institute Nodal Grant Awards ($50,000) 
• Stanford Cancer Institute Innovation Awards ($50,000)
  • Single PI
  • Multi PI collaboration leading to multi PI peer-reviewed funding
• Stanford Cancer Institute Pancreatic Cancer Innovation Awards ($50,000)
• Stanford Women's Cancer Center Innovation Awards ($50,000)
• NEW Shmunis Family Innovation Awards in Cancer Therapeutics ($50,000)

AWARD CATEGORY DESCRIPTIONS:

Stanford Cancer Institute Nodal Grant Awards (SCI-NGA) - $50,000
The SCI offers a funding mechanism, which aims to catalyze the planning and execution of multi-PI grants from the National Cancer Institute, including R01s, P01s and SPOREs. The funds are intended to be used to obtain proof of concept data and support planning activities.   

Stanford Cancer Institute Cancer Innovation Award (SCI-IA) - $50,000
The SCI offers awards to support projects focused on the acceleration of basic, translational, clinical and population-based cancer research and collaborations leading to multi PI peer-reviewed funding.

Stanford Cancer Institute Pancreatic Cancer Innovation Award (SCI-PCIA) - $50,000
The SCI offers awards leading to a greater understanding of pancreatic cancer, with the ultimate goal of improving the prevention or treatment of pancreatic cancer.

Stanford Women’s Cancer Center Innovation Award (SWCC-IA) - $50,000
With support from the fundraising efforts of Under One Umbrella, the SCI and the Stanford Women’s Cancer Center offer awards for research projects related to women’s cancers.

***NEW Stanford Cancer Therapeutics (SCI-CT)- $50,000
The SCI is pleased to offer these new awards focused on cancer drug development and cancer therapeutics.  We encourage proposals that are “high-risk, high-reward drug development projects” which enable researchers to develop and therapeutic modalities that could lead to early phase clinical trials and transformative new treatments for patients.

TIMELINE (Anticipated / Exact dates TBD)

RFA Announced:  July 15, 2021
Proposal submission deadline: October 20, 2021   
Notification of Selection: December 2021
Funding Period:  March 1, 2022 – February 28, 2023

PROGRAM PRIORITIES 

• Bold and creative research projects
• Research related to health disparities
• Multi-disciplinary collaboration, including collaborations involving Stanford faculty beyond the School of Medicine or inter-programmatic collaborations across the seven SCI research programs
• Potential to lead (or is already leading) to an investigator-initiated clinical trial
• Plans for submission of an external peer reviewed (preferably NCI) application

ELIGIBILITY: 

Faculty members of the SCI or of the Stanford University community with PI Status.

Instructors must be partnered with an SCI member with PI status. 

***If the PI is not a SCI member, the submission must include a letter of support from a sponsoring SCI member, who would also be a project collaborator.

Please note, University Research Agreements (URAs) now require COI (OPACS) for all Co-PIs. As a Co-PI on this project, your Conflicts of Interest (COI) needs to be done before this award amendment can be released in SERA. Please be sure to go into OPACS https://opacs.stanford.edu/ to complete your COI declarations for the noted project if you haven't done so.

IMPORTANT: If you are interested in submitting more than 1 project, please contact Gayle White at gwhite5@stanford.edu prior to proposal submission of either proposal. Seedfunding.stanford.edu will only allow 1 proposal per PI (sunet ID), per funding opportunity.

Apply here >>

The SCI seeks to increase the number of clinical, laboratory, and population researchers, who are carrying out cancer research with applicability to the basic biology, prevention, diagnosis or treatment of cancer, or to the quality of life of cancer patients. This critical source of funding enables trainees to complete their cancer research training while applying for extramural support. We strongly encourage candidates of diverse backgrounds to apply. Full announcement >>
 
EVALUATION CRITERIA
The most important criteria for the fellowship awards are that applicants:

1. Have clear evidence of intent to pursue an academic career, (prior research experience is a plus).
2.  Have a commitment to apply during the 2022 academic year for outside support from foundations, the NIH, or other sources. If outside support is obtained for the 2022 academic year while the application is reviewed and approved, it will be used to offset the SCI funds awarded.

ELIGIBILITY: 
The RFA is open to individuals who are completing their clinical or post-doctoral training and are pursuing clinical, laboratory, or population-based research projects with direct cancer relevance at Stanford University. These individuals are in the final year of their residency, completing a post-doctoral fellowship (PhD), or are at the completion of their 2-3 year clinical fellowship experience.

MAXIMUM FUNDING AMOUNT: 
$75000

TIMELINE:
RFA Posted: October 13, 2021
Application Due:  December 6, 2021
Award Announcements: January 2022
Funding Period: July 1, 2022 – June 30, 2023
 
The guidelines are attached and are also available on the Stanford Cancer Institute’s Funding webpage: http://med.stanford.edu/cancer/research/funding.html

APPLICATION FORMAT
Please include the following in the application:

1. Cover letter from the applicant stating career goals
   1. Arial 11-pitch font
   2. 1/2-inch margins all around
   3. Single spaced
2. Curriculum vitae (CV)3.   Letter of support stating the applicants’ qualifications and promise for an academic career.4.   Letter of support from a faculty member who has worked with the applicant, but is not directly involved in the research project.

 

PROGRAM PRIORITIES 

• Clear evidence of intent to pursue an academic career (prior research experience is a plus)
• Have a commitment to apply during the 2022 academic year for outside support from foundations, the NIH, or other sources. If outside support is obtained for the 2022 academic year while the application is reviewed and approved, it will be used to offset the SCI funds awarded.

Dr. Steve Artandi, the Director of the Stanford Cancer Institute, has established the following internal vetting process for all Stanford faculty interested in applying for this NCI OIA Award. Dr. Artandi and his internal review committee will review potential applications, which will be judged on the basis of an NIH biosketch with current funding and a 1-2 page outline of background and specific aims for the proposal. 
 
Although the number of applications per institution is not limited, applications must be vetted locally and a two page Letter of Nomination signed by Dr. Artandi is required. Institutional support for the faculty member's effort is also mandated. Applications that are missing a Letter of Nomination will not be reviewed by NCI.
 
Timeline:
Stanford Cancer Institute internal vetting process deadline: October 12, 2021 (see the internal vetting process guidelines below)
Notification of selection: October 18, 2021
For PIs given the approval to proceed with their full applications:
Letter of Nomination DRAFT to SCI Director: October 21, 2021
Institutional representative (RPM/RMG or CGO/OSR) deadline: October 28, 2021
Application receipt deadline: November 4, 2021
 
Program Guidelines: PAR-21-333
 
Amount of funding: Awards will be for $600,000 direct costs per year, plus applicable Facilities and Administrative (F&A) costs to be determined at the time of award. The total project period may not exceed 7 years.  
 
Purpose: 
The objective of the National Cancer Institute (NCI) Outstanding Investigator Award (OIA) is to provide long-term support to accomplished investigators with outstanding records of cancer research accomplishments who propose to conduct exceptional research. The OIA is intended to allow investigators the opportunity to take greater risks, be more adventurous in their lines of inquiry, or take the time to develop new techniques.  Candidates for the OIA must be nominated by their applicant organization.
 
Eligibility: Stanford faculty with PI eligibility (UTL, UML, and NTLR appointments)
 

1. Applications must be submitted by Institutions who have nominated a Program Director/Principal Investigator (PD/PI) with outstanding cancer research accomplishments during the last 5 consecutive calendar years.
2. The Institution-nominated PD/PI must have been a PD/PI or Project Leader of a research project (on a NIH-defined multi-project grant e.g., P01, P50, U54) excluding cores, on an eligible NCI research grant(s) continuously since September 2016. Continuous funding is defined as receiving a Notice of Award as PD/PI for an eligible NCI funded research grant in each Federal Fiscal Year beginning in FY 2016 onward. Continuous funding does not include grants in a funded or unfunded extension. Eligible NCI research grant mechanisms are defined as R01, R15, R33, R35, R37, P01, P50, U01, U54, UM1, U19, U10, DP1, and DP2.
3. Due to the nature of this award, applicants are required to devote at least 6 person months effort to the OIA. Applicants with administrative responsibilities or other duties inconsistent with this time commitment may apply but must reduce those other commitments to accept the award.
4. PDs/PIs with effort on other grant support will be expected to provide, as part of the Just-in-Time information, a detailed explanation describing how effort on his/her other grants will be adjusted, if necessary, to permit 6 person months on the OIA.
5. PD/PIs will need to renegotiate their time and effort on other grant support, if necessary, in order to accommodate the OIA level of effort.

 
In addition, grantee Institutions are expected to:

1. Provide clear and continuing substantial commitment to the PD/PI, for example providing at least 20% salary support for the duration of the award.
2. For New (Type 1) applications: agree to relinquish the PD/PI's existing NCI funded single PD/PI and single project research grants to allow them to be consolidated into the OIA. 

 
INTERNAL STANFORD CANCER INSTITUTE VETTING PROCESS - Submission Guidelines
 
By October 12, 2021, please submit one PDF file containing the following, in the order listed below, via email attachment to:

Gayle White
Stanford Cancer Institute
gwhite5@stanford.edu
 
File name: Last name_ Last name_NCI_OIA.pdf
 
Institutional representative: not applicable. You do not need to submit your internal proposal through your institutional official for approval. You may submit your internal proposal directly to Gayle White. 
 
1) Title page
NCI Outstanding Investigator Award (PAR-21-333)
PI name, title, department, email address
 
2) Research Proposal
1-2 page outline of background and specific aims for the full proposal.
 
3) NIH Biosketch 
With current and pending funding included.
 
Selection process:
A small committee at the Stanford Cancer Institute led by Dr. Artandi will decide which proposals should go forward based on merit.  They will select the applicants to represent Stanford University. 

Summary: Limited funding opportunity - a university-wide internal selection process is required. The purpose of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to encourage and retain outstanding graduate students recognized by their institutions for their high potential and strong interest in pursuing careers as independent cancer researchers. The award will facilitate the transition of talented graduate students into successful cancer research postdoctoral appointments and provide opportunities for career development activities relevant to their long-term career goals of becoming independent cancer researchers.
 
Number of applicants permitted: 1
 
Timeline:
Stanford Cancer Institute internal deadline: October 14, 2021 (see the internal submission guidelines below)
Date applicant to be notified by SCI to proceed with his/her application: October 21, 2021
Letter of Nomination DRAFT to SCI Director: October 28, 2021
Deadline for submission of application materials and completed PDRF form to the RMG Fellowship office: November 11, 2021
Application receipt deadline: November 18, 2021
 
NIH Program Announcement: RFA-CA-21-059
 
Purpose:
The objective of the NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) is to identify and encourage outstanding graduate students who are recognized by their institutions as having high potential and strong interest in pursuing careers as independent cancer researchers, and then to facilitate their successful transition to postdoctoral positions. The F99/K00 award is intended for individuals who require 1-2 years to complete their Ph.D. dissertation research training (F99 phase) before transitioning to mentored postdoctoral research training (K00 phase). Consequently, applicants are expected to propose an individualized research training plan for the next 1-2 years of dissertation research training and a plan for 3-4 years of mentored postdoctoral research and career development activities that will prepare them for independent cancer-focused research careers.
 
Amount of funding:

• For the F99/K00 award, individuals may receive up to 6 years combined support for both phases, which includes up to 2 years in the F99 fellowship phase and up to 4 years in the K00 career development phase..
• For the F99 phase, award budgets are composed of stipends, tuition and fees, and institutional allowance.
• For the K00 phase, award budgets are composed of salary and fringe benefits, tuition and fees, research and career development support, and indirect costs.
• Please see program guidelines for additional details regarding allowable and unallowable costs.

 
Eligibility:

• An applicant must be a citizen or a noncitizen national of the United States, or has been lawfully admitted for permanent residence (i.e., possess a currently valid Permanent Resident Card USCIS Form I-551, or other legal verification of such status), or be a non-U.S. citizen with a valid U.S. visa. For applications submitted on behalf of non-U.S. citizens with valid U.S. visas, the visa status during each phase of the F99/K00 award must allow the PD/PI to conduct the proposed research at the applicant institution. For the F99 phase of the award, the applicant F99 institution is responsible for determining and documenting, in the nomination letter, that the applicant's visa will allow the applicant to remain in the U.S. to complete the F99 phase of the award, and that there are no known obstacles that would prevent the applicant from obtaining a visa for the K00 phase.
• The applicant must have a baccalaureate degree and be currently enrolled as a graduate student in the third or fourth year of a mentored PhD or equivalent research degree program (e.g., DrPH, ScD) in the biomedical, behavioral, or clinical sciences at a domestic institution. F99 eligibility is determined from the date of enrollment as a graduate student at the PhD institution and includes the time spent to earn a MS degree unless there was a major change in research area and a change in research mentor.
• The F99/K00 award may not be used to support studies leading to the MD, DDS, or other clinical, health-professional degree (e.g., DC, DMD, DNP, DO, DPM, DVM, ND, OD, AuD). Students matriculated in a dual-degree program (e.g. MD/PhD, DO/PhD, DDS/PhD, or DVM/PhD) are not eligible for the F99/K00 program.
• Please see program guidelines for additional criteria regarding eligibility.

STANFORD INTERNAL SUBMISSION GUIDELINES:
 
By October 14, 2021, please submit one PDF file containing the following, in the order listed below, via email attachment to:

Gayle White
Stanford Cancer Institute
gwhite5@stanford.edu
 
File name: Last name_NCI_F99/K00.pdf
 
Institutional representative: not applicable. You do not need to submit your internal proposal through your institutional official for approval. You may submit your internal proposal directly to Gayle White. 
  
1) Title page
The NCI Predoctoral to Postdoctoral Fellow Transition Award (F99/K00) - RFA-CA-21-059
Nominee name, title, department, email address
Name of the Ph.D. program
Current year in the graduate program
Citizenship status or current Visa status
Nominator name, title, department, email address
 
2) Nomination letter
Letter must be prepared by the primary mentor, co-signed by the PI, and addressed to the Stanford Cancer Institute review committee.  This letter should confirm that the nominee will be at the dissertation research stage of training at the time of award, and must provide evidence of high academic performance in the sciences and commitment to a career as an independent cancer research scientist. The primary mentor must confirm his/her successful track record of mentoring predoctoral students.  If the applicant is not a U.S. Citizen or permanent resident, the sponsoring institution must include information about the candidate’s visa status, an assurance that the candidate’s visa provides sufficient time to complete the F99 phase of the award at a U.S. institution, and assurance that there are no known obstacles (e.g. home country requirement) to the candidate obtaining a visa at the time of the K00 transition.
 
3) Dissertation Research Project summary
Must be prepared by the nominee (one page limit)
 
4) Nominee's CV
 
Selection Process
The proposals will be reviewed by a Stanford Cancer Institute internal committee. The committee will select the applicant to represent Stanford.

The goal of the AGING Initiative is to bridge the Health Care Systems Research Network (HCSRN) with the Claude D. Pepper Older Americans Independence Centers (OAIC) to create a national resource to nurture and advance an interdisciplinary research agenda focused on older adults with multiple chronic conditions (MCCs). 

We are seeking one-year pilot project proposals to support activities that will increase the likelihood of successful future research proposals focused on older adults with MCCs. (Full program announcement) These include, but are not limited to the following priority areas:

1. Methodological issues relevant to analyses of the health impact or treatment of MCCs including the validity of empirical measures.
2. Methods to address inferential issues in observational data on treatment effects.
3. Novel methods to use information contained in electronic health records to construct new measures relevant to MCCs, their treatments and outcomes.
4. Public health and health care cost impacts of specific combinations of MCCs in defined older populations.
5. Effectiveness and safety of different therapeutic options for patients with specific combinations of MCCs.
6. Alterations in safety or effectiveness of a treatment for one condition related to the presence of one or more coexisting conditions.
7. Understanding health and access disparities related to MCCs.
8. MCCs and COVID-19: impact on morbidity and mortality in older adults.

New Priority Area for Funding in 2021 – 2022 Cycle: A new collaboration between US Deprescribing Research Network (USDeN) and the AGING Initiative will focus on the priority area of deprescribing among older adults with multiple chronic conditions. Proposals responding to this priority area will undergo a joint review by both the USDeN and the AGING Initiative. Applicants may apply to both the USDeN and the AGING Initiative, but may not receive funding from both organizations. (Please visit https://deprescribingresearch.org/network-activities/grantopportunities/ and https://theaginginitiative.wordpress.com/pilot-projects/ to learn more.) In the submission form, applicants will be asked to indicate if the proposal is applicable to the priority area of deprescribing among older adults with multiple chronic conditions.

Letter of Intent (LOI) Requirements

1. Specific Aims (one page)
2. Biosketch of proposed principal investigator (new NIH format)

Study Team Requirements: This opportunity is available to investigators affiliated with HCSRN research centers and/or the OAICs, as well as investigators currently or formerly in the AGING MCCs Scholars Program or USDeN Junior Investigator Intensive Program. Full specification of the study team is not required in the LOI. If invited to submit a full application, we encourage the inclusion of an early career investigator on the research team (e.g., someone who has not been PI of a large-scale NIH grant). Collaborations between HCSRN and OAIC affiliated investigators are also encouraged but not required.

Approval of your Letter of Intent is required to submit a full proposal for the Pilot Projects Program.

Additional Information— This one-year project will have a maximum of $40,000 budget (total costs). Up to 3 grants will be awarded in this cycle. More information about the AGING Initiative and the pilot grants can be found on our website: https://theaginginitiative.wordpress.com/pilot-projects/. There you can also register for the informational webinar, which will describe and address questions on the pilot project grants. Additionally, individuals who are interested in partnering with or engaging with a member of the AGING Patient/Caregiver Advisory Council for their project can complete the collaboration request form here. All queries should be addressed to Ivan Abi-Elias at (Ivan.Abi-Elias@meyersprimary.org).

LOI Review Criteria—In addition to the standard NIH scientific review criteria, pilot project review criteria include: (1) study relevance to older adults with MCCs and/or their caregivers; (2) leveraging OAIC-related data and/or the unique features of the HCSRN and its data; (3) methodological rigor and validity of findings (4) likelihood that the proposed study will be completed within one year; and (5) likelihood that the project will lead to submission of future research proposals.

Due Date—Completed letters of intent should be submitted electronically no later than 11:59 PM EDT/8:59 PM PDT on November 12, 2021. Apply >>

Review and Notification Schedule
LOI Submission Due Date: 11/12/2021
Invitations Sent for Full Applications: 12/17/2021
Full Applications Due (by invitation only) 02/25/2022

Note that start of funding is contingent on completion of human subjects review (after winning proposals are announced). 

The purpose of this Funding Opportunity Announcement (FOA) is to solicit applications to develop, adapt, and test individual-, community- or multilevel interventions to address modifiable risk factors for cancer in rural populations. Applications should focus on primary prevention and assess and address one or more of the social and behavioral risk factors that contribute to cancer disparities in rural populations: tobacco use; diet, physical activity and weight; alcohol use; UV exposure; and HPV vaccination. Applications should also assess and address myriad social determinants of health, cultural factors, and health care and technology access barriers that may contribute to rural cancer disparities. This FOA also encourages implementation science research, to incorporate efficacious cancer control interventions in a coordinated way, into broader, sustainable health programs that are designed to reach rural populations and allow local customization and adaptation.

Deadline: March 15, 2021; January 18, 2022

Read more or apply >>

PURPOSE
The FCRI Grant is designed for unique one-time investments in the most compelling, innovative research ideas that ultimately lead to the advancement of the practice of radiology. Full program announcement >>

AWARD
Total available funding up to $400,000. More than one proposal may be funded but the total for all awards is limited to $400,000. We invite applications up to $200,000 total budget (including indirects, capped at 15%).

NATURE OF PROJECTS
Projects are typically pilot or seed grant-type projects that test a new idea or help support a new area or direction of clinical research in radiology. These grants generally address a specific hypothesis, and generate preliminary data that could be used to justify or strengthen subsequent comprehensive applications to national peer-reviewed funding agencies. Successful applications will require collaboration with ACR and overall project sustainability. The project must utilize ACR staff expertise or systems and must outline a plan for future growth in science and funding.

ELIGIBILITY
Applicants must be current, in good standing members of the American College of Radiology. Individuals or groups may submit proposals. Grants are available to full-time faculty and trainees with an MD, DO, PhD, or equivalent degree in educational institutions within the United States. Applications must have support from the Chair of an ACR Research Committee*. ACR has research committees or institutes in the fields of Radiation Oncology, Oncologic Imaging, Molecular Imaging, Pediatric Imaging, Cardiothoracic radiology, Neuroradiology, Interventional Radiology, and Head Injury.

*ACR Staff will facilitate introductions of grant applicants to ACR Research Committee Chairs for a Letter of Support (LOS). Contact ACR Staff at Research@acr.org.

APPLICATION DEADLINE
Applicants are to submit their complete application via email to Research@acr.org. Applications must be received by ACR by 5 pm ET on January 13, 2022. Applications not submitted by this time or that are incomplete will not be considered.

This Request for Applications is associated with the Partnership for Accelerating Cancer Therapies (PACT), a project associated with the Beau Biden Cancer Moonshot ™ Initiative that is intended to accelerate cancer research.The overall goal for this Request for Applications (RFA) is to solicit clinical trials to partner with the PACT initiative to provide biospecimens for exploratory deep immunoprofiling analysis, employing this standardized set of biomarker assays. More information >>

The PACT partnership will consider supporting the deployment of the selected standardized biomarker assays in a broad range of IO trials. The group is encouraging trials from any cancer type that is comparing effects of immune therapy or immune therapy in combinations with another therapy. Examples of IO considered include, but are not limited to:

• Immune Checkpoint Inhibitors (ICIs)
• Other immune modulators
• Immunotherapy in combination immune modulators, targeted agents or chemotherapy/radiotherapy
• Adoptive Cell Therapy
• Immune vaccine therapies

Applications will be reviewed on a rolling basis and in order of submission. All applications must be received prior to January 31, 2022.

On October 30, 2017 the National Cancer Institute is pleased to announce the release of 17 new Cancer Moonshot funding opportunities. As you know, efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible.

Following receipt of the Blue Ribbon Panel report, NCI identified funding opportunity announcements (FOAs) from within its extensive research portfolio that address the goals of the Cancer Moonshot. These opportunities mark the beginning of a growing Cancer Moonshot portfolio which will continue to expand given the authorization of the 21st Century Cures Act to fund the Beau Biden Cancer Moonshot with $1.8 billion over 7 years. While the FOAs listed below highlight research initiatives that align with the efforts of the Cancer Moonshot, they may be supported with existing funds or with the 21st Century Cures funding.

On October 30, 2017 the National Cancer Institute is pleased to announce the release of 17 new Cancer Moonshot funding opportunities. As you know, efforts supported through the Cancer Moonshot aim to accelerate cancer research, making more therapies available to patients and improving the ability to prevent cancer and detect it the earliest stage possible. Learn more about these opportunities here.

Cancer Moonshot - UPDATED Funding Opportunities link